← Back to Search

Monoclonal Antibodies

Dupilumab for Severe Chronic Itching

Phase 2
Recruiting
Led By Jason Sluzevich, MD
Research Sponsored by Mayo Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Male and/or female subjects 18 years or older with chronic pruritus of moderate to severe severity in the setting of intrahepatic or extrahepatic cholestatic liver disease. Chronic is defined as greater than 6 weeks of symptom duration. Pruritus severity is based on the peak pruritus numerical rating score of ≥ 4 (moderate severity).
Be older than 18 years old
Must not have
Pruritus due to a primary inflammatory skin dermatosis or other forms of psychogenic pruritus utilizing skin biopsies as needed.
Any form of chronic hepatic pruritus associated with underlying malignancy
Timeline
Screening 3 weeks
Treatment Varies
Follow Up this will be assessed at week 6,12,18
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing if a medication called dupilumab can help treat moderate to severe chronic itching of the skin.

Who is the study for?
This trial is for adults over 18 with moderate to severe itching due to liver disease lasting more than 6 weeks. Participants must be able to follow the trial procedures and not have a history of certain conditions like liver malignancy, past liver transplants, or specific types of pruritus. Pregnant individuals and those with severe asthma or allergies to dupilumab are excluded.
What is being tested?
The trial is testing Dupilumab, an injectable medication, for its effectiveness in treating chronic itching associated with liver disease. The goal is to see if this drug can provide relief from persistent and intense itching.
What are the potential side effects?
Dupilumab may cause side effects such as allergic reactions at the injection site, eye inflammation or irritation, cold sores in your mouth or on your lips, and potentially other immune system-related issues.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 or older with long-term severe itching due to liver disease.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have itching due to skin inflammation or a psychological condition.
Select...
I experience chronic itching due to liver-related cancer.
Select...
I have received a liver transplant.
Select...
I am under 18 years old.
Select...
I have a known worm infection.
Select...
I do not have severe asthma that needs high-dose steroids.
Select...
I am currently taking selective opioid antagonists.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~this will be assessed at week 6,12,18
This trial's timeline: 3 weeks for screening, Varies for treatment, and this will be assessed at week 6,12,18 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Peak Pruritus Numerical Rating Score (PRNS)
Secondary study objectives
Improvement in weekly average Peak Pruritus Numerical Rating Score (PRNS) ≥3 from baseline.
Improvement in weekly average Peak Pruritus Numerical Rating Score (PRNS) ≥4 from baseline.
Verbal rating scale (VRS)

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: DupilumabExperimental Treatment1 Intervention
Subcutaneous (SC) dupilumab selected for this study is 300 mg every 2 weeks for 18 weeks.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Dupilumab 300Mg Solution for Injection
2020
Completed Phase 2
~50

Find a Location

Who is running the clinical trial?

Mayo ClinicLead Sponsor
3,343 Previous Clinical Trials
3,062,337 Total Patients Enrolled
Regeneron PharmaceuticalsIndustry Sponsor
671 Previous Clinical Trials
386,490 Total Patients Enrolled
Jason Sluzevich, MDPrincipal Investigator - Mayo Clinic
Mayo Clinic Hospital Jacksonville
Yale University School Of Medicine (Medical School)
University Hosp, Inc (Residency)
1 Previous Clinical Trials
12 Total Patients Enrolled

Media Library

Dupilumab (Monoclonal Antibodies) Clinical Trial Eligibility Overview. Trial Name: NCT04256759 — Phase 2
Itching Research Study Groups: Dupilumab
Itching Clinical Trial 2023: Dupilumab Highlights & Side Effects. Trial Name: NCT04256759 — Phase 2
Dupilumab (Monoclonal Antibodies) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04256759 — Phase 2
~0 spots leftby Dec 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top